CellAct Pharma GmbH is a venture backed biotech company focused on the development of innovative therapeutics for the treatment of diseases with high unmet need, especially of certain cancers and inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis.
CellAct's drug candidates, for which the company holds exclusive IP rights, target and modulate certain human molecules (such as TIRC7, CEACAM1, HLA class II and topoisomerase II) which have specific functions in the immune response and/or tumor growth.
|Company name||Cellact Pharma GmbH|
|Zip Code & City||44227 Dortmund|
Wissenschafts- und Technologiecampus
|Name||Dr. Nalan Utku|